Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its fourth quarter and year-end 2021 financial results on February 28, 2021, before markets open. A conference call/webcast will be held at 8:30 am ET to discuss the results and the company's outlook for 2022. Aurinia focuses on therapies for serious diseases with high unmet needs, having launched the first FDA-approved oral treatment for active lupus nephritis in January 2021.

Positive

• Introduced the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Negative

• None.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its fourth quarter and year end 2021 financial results on Monday, February 28, 2021, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review the Company’s 2021 financial results, provide a general business update and discuss the Company’s outlook for 2022.

Interested participants can dial +1-877-407-9170 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005894/en/

Investor and Corporate Contact:

Dana Lynch, IR & Corporate Communications

dlynch@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When will AUPH release its fourth quarter 2021 financial results?

Aurinia Pharmaceuticals Inc. will release its fourth quarter financial results on February 28, 2021.

What time is the AUPH conference call for financial results?

The conference call/webcast for Aurinia's financial results will be held at 8:30 am ET on February 28, 2021.

What is the significance of Aurinia's recent FDA approval?

Aurinia launched the first FDA-approved oral therapy for active lupus nephritis in January 2021, marking a significant milestone for the company.

How can I access the AUPH financial results webcast?

The audio webcast can be accessed through the 'News/Events' section of Aurinia's corporate website.